158 results about "Demyelinations" patented technology

Method for reversing demyelination in a patient having a demyelinating disorder may include detecting one or more biomarkers for demyelination from the patient, receiving, in an implanted vagus nerve stimulator, a command to apply a remyelinating stimulation to the patient based on a level of the detected one or more biomarkers for demyelination; and applying electrical stimulation to the patient's vagus nerve from the implanted vagus nerve stimulator to reverse demyelination and increase remyelination of the patient's nerves. The electrical stimulation may be adjusted based on the level of the detected one or more biomarkers.

Systems, devices, and methods for using vagus nerve stimulation to treat demyelination disorders and / or disorder of the blood brain barrier are described. The vagus nerve stimulation therapy described herein is configured to reduce or prevent demyelination and / or promote remyelination to treat various disorders related to demyelination, such as multiple sclerosis. A low duty cycle stimulation protocol with a relatively short on-time and a relatively long off-time can be used.

The use of α-ketoglutaric acid in the preparation of a drug for preventing and treating demyelination-related diseases. The α-ketoglutaric acid or a derivative thereof is used for preventing and / or treating myelin sheath defects in demyelination-related diseases, such as demyelinating diseases, amyotrophic lateral sclerosis, Huntington's disease, hypomyelinating leukodystrophy, Alzheimer's disease, Parkinson's syndrome and diabetes-related visual impairment, and can promote myelin sheath generation, regeneration or repair, and improve the immune microenvironment in the lesion area.

The present disclosure discusses systems and methods for identifying biomarkers that can help with the diagnosis, prognosis, and treatment choices of patients with neurodegenerative diseases. Diffusion based magnetic resonance imaging can often fail for patients with a neurodegenerative disease because parameters fractional anisotropy, mean diffusivity, and radial diffusivity are based on simple models that can fail in the presence of neurodegeneration, such as demyelination. The present disclosure discusses systems and methods that enhance dMRI images and enable tractography to be performed on images of a damaged nervous system. The damaged tracks identified by the present system can be used as a biomarker for the assessment of patients. In some implementations, the biomarkers are converted into clinical scales that can be used to compare patients to one another or over time.

The invention belongs to the technical field of biological medicine, and particularly relates to a single-domain antibody VHH-L1 targeting LINGO-1 protein, and the amino acid sequence of the single-domain antibody VHH-L1 is shown as SEQ ID NO: 1. The single-domain antibody has nanomole-level high affinity and excellent specificity, can effectively block the interaction between LINGO-1 and ligands thereof, and remarkably promotes differentiation and myelination of oligodendroglia cells. The invention further provides a neural stem cell subjected to genetic engineering modification, and the neural stem cell can stably and continuously secrete the single-domain antibody VHH-L1. In a spinal cord injury animal model, the engineered stem cell shows an excellent treatment effect, can significantly promote motor function recovery, axon regeneration and myelin sheath repair, and effectively inhibits glial scar formation. The double advantages of cell therapy and long-acting protein delivery are fused, and a brand new efficient treatment strategy is provided for demyelination diseases such as multiple sclerosis and spinal cord injury.

A system for treating a subject including a signaling device, a controller, and a stimulator. The signaling device is in communication with the input of the controller and is configured to send a signal to the controller. The stimulator is in communication with the output of the controller and is configured to stimulate an auricular branch of a vagus nerve in an ear of a subject in response to the controller receiving the signal from the signaling device.

The present invention relates generally to methods of using nalfurafine for treating and / or preventing demyelinating disease in a subject, and in particular for treating and / or preventing multiple sclerosis (MS). Also disclosed is nalfurafine for use in treating and / or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalfurafine for use for treating and / or preventing demyelinating disease in a subject, and in particular for treating and / or preventing MS.

The present invention belongs to the field of biomedical technology, and particularly relates to the use of dendritic cells in the prevention and / or treatment of demyelinating diseases. The expression level of Talin1 protein in the dendritic cells is reduced or not expressed. Loading the dendritic cells with myelin peptides can safely and effectively alleviate immune inflammation and nerve damage, and thus is expected to develop into a new therapy for the prevention and / or treatment of demyelinating diseases.

The invention features compositions and methods for treating diseases or disorders associated with undesirable neuronal excitability (e.g., de-myelinating disease, neurodegenerative disease, such as Parkinson's disease or Huntington's disease; or chronic pain, or epilepsy).

A method for determination of an indicator representative of a change in the brain caused by a demyelinating disease, the method including, for each region of interest of the brain, determining a regional coefficient of one of the following diffusion coefficients: the radial diffusion, the axial diffusion, the mean diffusion, the anisotropy fraction, or a combination of several of these coefficients, the regional coefficients being determined from a diffusion MRI image; determining a number of changed regions, for which a condition relating to the value of the regional diffusion coefficient of each region is satisfied; and determining the indicator in accordance with the number of changed regions.

Disclosed herein are methods and compositions for treating a demyelinating disease, such as multiple sclerosis, by administering to a subject suffering from the disease at least one Retinoid X receptor gamma (RXRy) agonist and at least one member selected from a Liver X Receptor (LXR) antagonist, CYP51 inhibitor, TM7SF2 inhibitor, EBP inhibitor, and combinations thereof.

The present invention provides the use of the small molecule compound 2-D08 in the preparation of a drug for treating or preventing demyelinating diseases. As a small molecule compound, 2-D08 has a small molecular weight and is easily permeable through the blood-brain barrier to exert central pharmacodynamic effects. Moreover, the chemical synthesis method of 2-D08 is also very mature, which is conducive to reducing the preparation cost of drugs for treating demyelinating diseases, thereby alleviating the medical expenses of patients to a certain extent. 2-D08 can promote the regeneration of myelin sheaths of spinal cord axons, significantly improve the motor ability and nerve function recovery of mice, and is expected to become a disease-modifying treatment drug targeting the origin of brain damage in MS patients, with brain permeability and ion channel selectivity, and has very broad application prospects.

The application belongs to the technical field of medicine, and particularly relates to application of echinacoside in preparation of a medicine for preventing or treating a demyelination disease; the echinacoside can promote differentiation and maturation of OPCs to OLs, promote proliferation of OLs, promote myelin repair, improve pathological changes of myelin ultrastructure, and promote myelin thickness to return to a normal level; the scheme provides a new treatment means for preventing or treating the demyelination disease, and is expected to reverse disability caused by myelin shedding or damage.

To provide a drug having positive effects in subjects suffering from neurological diseases, including neurodegenerative diseases, demyelinating diseases, neuro ischemic diseases and neuromuscular diseases.SOLUTION: Dextran sulfate, or a pharmaceutically acceptable derivative thereof, is used to induce differentiation of glial cells and neurons.SELECTED DRAWING: Figure 12

Described herein are compositions for treating human patients exhibiting hyperactivity of PAD enzymes, hypercitrullination and / or a neurodegenerative disease exhibiting a demyelinating condition, or treating multiple sclerosis in human patients in need thereof. Also described herein are methods of treating a human patient exhibiting hyperactivity of PAD enzymes, hypercitrullination and / or a neurodegenerative disease exhibiting a demyelinating condition, or multiple sclerosis in human patients in need thereof, including orally administering to the patient once or twice daily a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

This invention provides the use of a trisaccharide compound with a core structure of GlcN(1→4)IdoA(1→4)GlcNS in the preparation of a medicament for the treatment or prevention of multiple sclerosis. The compound can delay the onset of clinical symptoms in patients, reduce or alleviate or improve patients' clinical symptoms and signs, improve or inhibit nerve demyelination, and improve or inhibit inflammation of the central nervous system.

The invention belongs to the technical field of medicines, and discloses application of a compound M1 shown as a formula (I) and pharmacodynamically acceptable salt thereof in preparation of medicines for preventing, relieving and / or treating autoimmune demyelination diseases. On a mouse experimental autoimmune encephalomyelitis model, the compound M1 shows a good treatment effect, can effectively prevent and treat pathological changes and disease progression of diseases, relieve the severity of the diseases and inhibit LPS-stimulated microglial BV2 cells from releasing inflammatory mediators, and provides a new drug and a new structure for clinical treatment.

The disclosure provides methods for (i) treating multiple sclerosis in patient, (ii) treating a patient having symptoms of multiple sclerosis, (iii) preventing the onset of multiple sclerosis symptoms in patient having multiple sclerosis or predisposed to multiple sclerosis; (iv) promoting or enhancing immunomodulation and remyelination and / or myelin repair in a subject in need thereof; (v) a neuroinflammatory disorder; (vi) Amyotrophic Lateral Sclerosis; or (vii) a demyelinating disease or disorder or a hypomyelinating condition, each method comprising administering a therapeutically effective amount of a bryostatin compound to the patient.

Disclosed are N-(phenyl)-1H-indole-3-sulfonanmide and N-(phenyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide derivatives of formula I substituted at the 1- and 6-positions of the 1H-indole or 1H-pyrrolo[2,3-b]pyridine moiety, as well as structurally related compounds (e.g. the N-pyridin-2-yl and the N-pyridin-3-yl analogues thereof). The present compounds have GPR17 modulating properties which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating disorders such as multiple sclerosis.

The invention relates to the technical field of new application of medicines, in particular to application of G15 to treatment of white matter injury based on promotion of cerebrovascular generation, and finds that the G15 has the effect of promoting cerebrovascular generation, can promote myelination insufficiency caused by hypoxia in the early development stage and can improve neurological dysfunction caused by hypoxia, and the G15 has the effect of promoting cerebrovascular generation. Moreover, myelin sheath regeneration of a local demyelination area after the adult can be promoted, so that the effect of directly treating the white matter injury from the pathological aspect is achieved. The invention provides a new application of G15 in treating white matter injury and long-term neurological dysfunction by promoting cerebrovascular generation.

The invention belongs to the field of medicine, and discloses application of bilirubin in preparation of a medicine for treating central nervous system autoimmune diseases, the bilirubin can relieve the clinical symptom severity of the central nervous system autoimmune diseases, relieve the demyelination injury severity of the central nervous system autoimmune diseases, and improve the curative effect of the central nervous system autoimmune diseases. The composition can be used for relieving microglial cell activation in the central nervous system autoimmune diseases, relieving inflammatory cell infiltration in the central nervous system autoimmune diseases and relieving neuroinflammatory response in the central nervous system autoimmune diseases. Good clinical application values are realized.

Provided herein are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of TUBB4A RNA and, in some cases, the amount of TUBB4A protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful for ameliorating at least one symptom of a disease or condition associated with TUBB4A. Such symptoms and markers include hypomyelination, demyelination, dysphonia, myodynia, ataxia, spasm, cerebellar and / or basilar joint atrophy, hypopsia, stiffness, microcephalic deformity, focal cortical dysplasia, seizures, and kindergarten death.

Provided herein are compounds and pharmaceutical compositions thereof for inhibiting emopamil binding protein (EBP), and the use of the compounds and pharmaceutical compositions thereof in the treatment of demyelinating diseases, such as multiple sclerosis.

The invention relates to the field of biological medicine, in particular to application of a reagent for up-regulating PEX5 expression level or improving PEX5 protein activity in preparation of a medicine for treating demyelination diseases. A lentivirus infection experiment and lysolecithin are utilized to induce a mouse demyelination model, it is found that PEX5 can promote differentiation and maturation of oligodendroglia cells and remyelination and repair of demyelination mice, and ganciclovir can promote differentiation of the oligodendroglia cells and effectively relieve demyelination diseases by promoting expression of PEX5. PEX5 can be used as a drug intervention target, and a drug for promoting expression or function of PEX5 can be used as a potential therapeutic drug for demyelination diseases.

This invention relates to the field of biomedical technology, and provides the application of compound LY2940094 in the preparation of drugs for treating demyelinating diseases of the central nervous system. This invention verifies through modern biological techniques that compound LY2940094 can promote the differentiation of oligodendrocyte precursor cells (OPCs) into mature oligodendrocytes (OLs), thereby promoting the regeneration of myelin in the central nervous system and thus treating demyelinating diseases of the central nervous system.

The present application provides O-GlcNAc glycosidase (O-GlcNAcase, OGA) inhibitors and their applications for promoting remyelination. Specifically, by comparing the promoting effects of different types of OGA inhibitors on OPC differentiation and remyelination in the models of OPC differentiation and remyelination, the OGA inhibitors with drugability of the present application are obtained. The OGA inhibitors of the present application have wide application value in preventing and / or treating demyelination and its related diseases.

Disclosed is a protein comprising no more than three human autoantigenic proteins, wherein a first human autoantigenic protein comprises a truncated myelin oligodendrocyte glycoprotein (MOG) amino acid sequence, a second human autoantigenic protein comprises a myelin basic protein (MBP) amino acid sequence, and a third human autoantigenic protein comprises a truncated proteolipid protein (PLP) amino acid sequence. Also disclosed are related nucleic acids, pharmaceutical compositions, methods of treating a demyelinating disease, and methods of producing the proteins.

The invention belongs to the technical field of medicines, and discloses application of a compound M0 as shown in a formula (I) and pharmacodynamically acceptable salts thereof in preparation of medicines for preventing, relieving and / or treating autoimmune demyelination diseases. On a mouse experimental autoimmune encephalomyelitis model, the compound M0 shows a very good treatment effect, can effectively prevent and treat pathological changes and disease progression of diseases, relieve the severity of the diseases and inhibit LPS-stimulated microglial BV2 cells from releasing inflammatory mediators, and provides a new drug and a new structure for clinical treatment. # imgabs0 #

4-Hydroxyphenyl-2H-indazol-5-ol compounds are estrogen receptor beta ligands that have immunomodulatory properties and increase oligodendrocyte survival, differentiation, and remyelination. The compounds, compositions, and kits are useful in the treatment of multiple sclerosis and endometriosis.